NCT00617799 2023-10-10
Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma
University of Nebraska
Completed
Clinical Trials
12 trialsNCT04285749 2020-07-27
Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Withdrawn
NCT00898183 2018-06-28
S9431: Studying Genes and Immune Response in Tumor Samples From Patients With Locally Advanced or Metastatic Melanoma
SWOG Cancer Research Network
Completed
NCT00937781 2017-05-17
Study of Tumor Tissue From Patients With Melanoma Treated on Clinical Trial EST-1690
Eastern Cooperative Oncology Group
Completed
NCT01209299 2017-05-17
Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate
Eastern Cooperative Oncology Group
Completed
NCT00991991 2016-05-17
Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma
Case Comprehensive Cancer Center
Terminated
NCT00565968 2015-03-06
Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg
Duke University
Phase 1 Completed
NCT00445783 2013-08-12
Study of Families With Melanoma
National Cancer Institute (NCI)
Unknown
NCT00672321 2013-08-12
Answering Questions About Vitamin D Supplementation and Sun Exposure in Patients Who Have Undergone Surgery for Stage IB, Stage II, or Stage IIIA Melanoma
National Cancer Institute (NCI)
Unknown
NCT00897481 2013-08-12
Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy
National Cancer Institute (NCI)
Unknown
NCT00492440 2012-10-18
Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer
Cytheris SA
Phase 1 Terminated
NCT00811759 2010-10-07
Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma
National Cancer Institute (NCI)
Phase 1/2 Unknown